Skip to main content
. 2023 Aug 1;133(15):e169583. doi: 10.1172/JCI169583

Figure 4. ILC2s contribute to exaggerated type 2 immune responses in Plscr1-null mice.

Figure 4

WT and Plscr1–/– mice were subjected to HDM administration (25 μg HDM 3 times a week for 3 weeks). In A–C, mice were treated with IL-33 siRNA (every other day, 3 nmol/mouse) or its scrambled control. In (D–F), Plscr1–/– mice were bred with RoRαfl/fl mice and IL-7Rcre mice. (A and D) Lung ILC2 recovery was assessed by flow cytometry. (B and E) BAL IL-13 levels were measured by ELISA. (C and F) BAL eosinophil recovery was assessed. (G) WT and Plscr1–/– mice were treated with 1 μg IL-33 i.n. daily for 5 consecutive days to allow in vivo ILC2 amplification. 5×105 ILC2s were inoculated i.n. to RoRαfl/fl/IL-7Rcre mice. Mice were challenged with HDM 1 day after ILC2 adoptive transfer. (H) BAL IL-13 levels were measured by ELISA. (I) BAL eosinophil recovery was assessed. Values are mean± SEM with 4–7 mice in each group. Comparisons between groups were conducted by 2-way ANOVA with Bonferroni’s posthoc test. *P ≤ 0.05, **P ≤ 0.01. ***P ≤ 0.001.